ization of intangible assets 190 6
Total operating expenses 6,112 5,858
Loss from operations (1,699) (416)
Interest income, net 306 464
Other income (expense) (2) 26
Net income (loss) $(1,395) $74
Net income (loss) per share:
Basic and diluted $(0.07) $0.00
Weighted average shares outstanding:
Basic 18,931 18,815
Diluted 18,931 19,200
Stock-based compensation expense is
included in the above as follows:
Cost of DIS revenue $17 $25
Cost of Product revenue 11 26
Research and development 13 23
Sales and marketing 24 50
General and administrative 115 150
Digirad Corporation
Condensed Consolidated Balance Sheets(1)
(in thousands)
March 31, December 31,
2008 2007
(unaudited)
Assets
Cash and cash equivalents $15,568 $14,922
Securities available-for-sale 8,304 16,740
Accounts receivable, net 9,772 8,536
Inventories, net 5,804 5,455
Other current assets 2,133 1,786
Total current
'/>"/>
SOURCE Digirad Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine news :1.
Digirad Corporation to Release First Quarter Financial Results on April 24, 20082.
Digirad Corporation Appoints John W. Sayward to Its Board of Directors3.
Digirad Corporation to Release Fourth Quarter, Year-End Financial Results on February 7, 20084.
Digirad to Introduce New Clinical Standard for Cardiac SPECT5.
Digirad Corporation Board of Directors Appoints R. King Nelson Chairman6.
Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement7.
Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results8.
Digirad Corporation Named to Deloitte Technology Fast 509.
Digirad Corporation to Release Third Quarter, Nine-Month Financial Results on October 25, 200710.
The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future11.
STERIS Corporation Declares Regular Quarterly Dividend